Liver Cancer | Tumor

Two-Drug Combo Shows Modest Benefit in Biliary Tract Cancer

June 15th 2021, 9:00pm

Article

Treatment with the combination of Stivarga and Bavencio was associated with minor anti-tumor activity in patients with advanced, heavily pretreated biliary tract solid tumors.

Onivyde Combo Improves Outcomes for Patients with Metastatic Liver Cancer

June 8th 2021, 8:00pm

Article

Onivyde combined with a chemotherapy agent and a chemotherapy-protective drug should be used as a second-line treatment option in patients with metastatic liver cancer, according to an expert.

5 Recent Cancer Drug Approvals That Patients May Have Missed

June 3rd 2021, 1:00pm

Article

The Food and Drug Administration has had a busy couple of weeks, approving several agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.

FDA Grants Approval for Truseltiq for Metastatic Cholangiocarcinoma Treatment

May 29th 2021, 1:52pm

Article

The FDA approved a kinase inhibitor for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other arrangement.

Second-Line Chemotherapy Combo Shows Survival Benefit in Patients With Advanced Liver Cancer

May 26th 2021, 9:00pm

Article

The study results, according to the authors, suggest that the combination of folinic acid plus the chemotherapies fluorouracil and oxaliplatin should become the standard-of-care therapy in patients with advanced biliary tract cancer whose disease progressed with cisplatin and gemcitabine.

Neoadjuvant Libtayo Shows Promise for Patients With Hepatocellular Carcinoma

May 10th 2021, 3:00pm

Article

Twenty percent of patients with resectable hepatocellular carcinoma had a significant amount of cell death when receiving Libtayo before surgical intervention.

Derazantinib May Demonstrate Promising Disease Control in Some Patients With Cholangiocarcinoma

May 7th 2021, 9:00pm

Article

Interim results from a phase 2 study demonstrated that patients inoperable or advanced intrahepatic cholangiocarcoma and a FGFR2 gene mutation had a disease control rate of 79% when treated with derazantinib.

FDA Panel Votes to Uphold One Accelerated Drug Approval, and Overturn Another in Treatment of Advanced Liver Cancer

May 4th 2021, 3:00pm

Article

Members of an FDA committee recently voted in favor of upholding Keytruda’s accelerated approval indication for the treatment of patients with advanced hepatocellular carcinoma who had previously received treatment with Nexavar. However, the committee narrowly voted against maintaining Opdivo’s accelerated approval in the same patient population.

Tag Teaming Liver Cancer Care

April 30th 2021, 9:00pm

Article

As part of the “Speaking Out” video series, CURE® spoke with Dr. Laura M. Kulik about the basics of liver cancer, highlighting the need for a multidisciplinary approach to care.

CURE’s Clinical Trial Corner: April 2021

April 29th 2021, 1:00pm

Article

Here is a list of some recent trials that launched within the cancer space in April.